Circulatory System Drugs

Valsartan is a specific angiotensin Ⅱ (AT1) receptor antagonist. It is also a non skin AT1 receptor antagonist after losartan. It plays a key role in regulating systemic blood pressure and maintaining electrolyte and body fluid balance. It selectively acts on AT1 receptor subtypes and blocks the binding of Ang Ⅱ to AT1 receptor (its specific antagonistic effect against AT1 receptor is about 20000 times greater than that of AT2 receptor), thus inhibiting vasoconstriction and aldosterone release, resulting in hypotensive effect, but not inhibiting aldosterone release induced by potassium ion (K +). The antihypertensive effect is superior to enalapril in the treatment of hypertension, mild to moderate essential hypertension, especially for secondary hypertension caused by kidney damage. It can significantly reduce proteinuria in hypertensive patients with normal diabetes or normal renal function, and has the protective effect of promoting uric acid and urinary sodium excretion. It is also suitable for reducing the cardiovascular mortality of high-risk patients (left ventricular failure or left ventricular dysfunction) after heart attack.

This product can be widely used in food, cosmetics, dietary supplements and other industries. Coenzyme drugs are also important antioxidants and immune enhancers.

Atorvastatin calcium is a HMG CoA reductase inhibitor. Mainly through inhibiting the synthesis of HMGCoA reductase, thus inhibiting the synthesis of cholesterol in vivo, reducing the content of serum low density lipoprotein cholesterol and triglyceride. Atorvastatin calcium can inhibit the synthesis of cholesterol, interfere with the production of lipoprotein, reduce the level of serum total cholesterol, effectively reduce the level of serum triglyceride, but also increase the level of serum high-density lipoprotein cholesterol. It can reduce the plasma LDL-C level in some homozygous familial hypercholesterolemia patients, but this type of population has little response to other lipid-lowering drugs. It is clinically used for primary hypercholesterolemia, mixed hyperlipidemia, hypertriglyceridemia, homozygous familial hypercholesterolemia and prevention and treatment of atherosclerosis.

Irbesartan is an angiotensin II receptor inhibitor, which can be divided into AT1 and AT2. Irbesartan can inhibit the transformation of Ang Ⅰ into ang Ⅱ by selectively blocking the AT1 receptor of ANGLI, and specifically antagonize the angiotensin converting enzyme 1 receptor. The antagonism of irbesartan to AT1 is 8500 times that of AT2, It can inhibit the vasoconstriction and the release of aldosterone. This product does not inhibit angiotensin converting enzyme, renin, other hormone receptors, and ion channels related to blood pressure regulation and sodium balance. Irbesartan is the most effective drug in the treatment of hypertension and cardiovascular disease.

Telmisartan is a new type of antihypertensive drug, which is a specific angiotensin II receptor antagonist for the treatment of essential hypertension. The substitution of angiotensin Ⅱ receptor for at Ⅰ receptor subtype has high affinity binding. Telmisartan has no agonist effect at the at I receptor site, but selectively binds to at I receptor, which is persistent. It has no affinity for other receptors. The function of other receptors mentioned above is unknown, and the possible receptor hyperstimulation effect caused by telmisartan is also unknown. Telmisartan did not inhibit plasma renin or block ion channels. It did not inhibit angiotensin converting enzyme II, which could also degrade bradykinin induced adverse reactions.